Advice

Following an abbreviated submission

brinzolamide (Azopt) eye drops are accepted for use within NHS Scotland to decrease elevated intraocular pressure in ocular hypertension and open-angle glaucoma as monotherapy in patients unresponsive to beta-blockers or in patients in whom beta-blockers are contraindicated, or as adjunctive therapy to beta-blockers or prostaglandin analogues.

This abbreviated submission relates to a licence extension to cover use of brinzolamide with prostaglandin analogues. For patients in whom brinzolamide is an appropriate choice of therapy, this licence extension is not associated with a price increase and is not expected to increase drug usage.

Download detailed advice44KB (PDF)

Download

Medicine details

Medicine name:
brinzolomide 10mg/ml eye drops, suspension (Azopt)
SMC ID:
546/09
Indication:
Elevated intraocular pressure in ocular hypertension & open-angle glaucoma. Monotherapy in patients unresponsive to beta-blockers or where beta-blockers are contraindicated. Adjunctive therapy to beta
Pharmaceutical company
Alcon Laboratories UK Ltd
BNF chapter
Eye
Submission type
Abbreviated
Status
Accepted
Date advice published
14 April 2009